Anti-Aprotinin
Mouse monoclonal antibody
Cat.No. ABS 037-18
Preparation: Protein-A/G purified
Content: Available in 200 µL and 1 mL size.1 mg/mL +/- 15%. See Certificate of Analysis for details.
Solvent: 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage: 4-8ºC without exposure to light. No precautions necessary during handling.
Aprotinin, also called bovine pancreatic trypsin inhibitor, is a single chain globular Kunitz-type serine proteinase inhibitor found in bovine pancreas, parotid gland and lung. It forms stable, enzymatically inactive complexes with trypsin, chymotrypsin, plasmin and kallikrein. Aprotinin has been used therapeutically as an antifibrinolytic agent under the name Trasylol (Bayer) to reduce blood loss during cardiopulmonary bypass surgery but this use has been associated with an increased frequency of acute renal injury (1).
Aprotinin from bovine lung adsorbed onto aluminum hydroxide gel
ABS 037-18 binds bovine aprotinin immobilized on a solid phase or free in solution.
The epitope of ABS 037-18 is different from the epitopes of ABS 037-21 and ABS 037-35
ABS 037-18 (as biotinylated detection antibody e.g. at 1 µg/mL) forms an antibody pair with ABS 037-21 (as capture antibody) for high-sensitivity sandwich ELISA of aprotinin at sample concentrations of 0.6-20 µg/mL. Aprotinin in urine diluted 1/1000 can be assayed against standards in buffer. For assay in plasma it is recommended to add aprotinin-free control plasma to the standards to match the plasma sample dilution.
ABS 037-18 also forms an antibody pair with ABS 037-35 (as capture antibody) for sandwich ELISA of aprotinin at sample concentrations of 4-250 µg/mL. Both urine and plasma samples diluted 1/1000 can be assayed against standards in buffer. PBS-buffers are unsuitable for these assays and 0.2 M glycine sodium buffer, pH 8.8, is recommended.
| Method | Usability | References |
| ELISA | Yes | |
| Immunoblotting | Yes | |
| Immunohistochemistry | Not determined |
1. Mangano DT, Tudor IC, Dietzel C (2006) The risk associated with aprotinin in cardiac surgery. N. Engl. J. Med. 354: 353-365.